Literature DB >> 29938245

Overview of Japanese encephalitis disease and its prevention. Focus on IC51 vaccine (IXIARO®).

D Amicizia1, F Zangrillo1, P L Lai1, M Iovine1, D Panatto1.   

Abstract

Japanese encephalitis (JE) is a vector-borne disease caused by the Japanese encephalitis virus (JEV). JEV is transmitted by mosquitoes to a wide range of vertebrate hosts, including birds and mammals. Domestic animals, especially pigs, are generally implicated as reservoirs of the virus, while humans are not part of the natural transmission cycle and cannot pass the virus to other hosts. Although JEV infection is very common in endemic areas (many countries in Asia), less than 1% of people affected develop clinical disease, and severe disease affects about 1 case per 250 JEV infections. Although rare, severe disease can be devastating; among the 30,000-50,000 global cases per year, approximately 20-30% of patients die and 30-50% of survivors develop significant neurological sequelae. JE is a significant public health problem for residents in endemic areas and may constitute a substantial risk for travelers to these areas. The epidemiology of JE and its risk to travelers have changed, and continue to evolve. The rapid economic growth of Asian countries has led to a surge in both inbound and outbound travel, making Asia the second most-visited region in the world after Europe, with 279 million international travelers in 2015. The top destination is China, followed by Thailand, Hong Kong, Malaysia and Japan, and the number of travelers is forecast to reach 535 million by 2030 (+ 4.9% per year). Because of the lack of treatment and the infeasibility of eliminating the vector, vaccination is recognized as the most efficacious means of preventing JE. The IC51 vaccine (IXIARO®) is a purified, inactivated, whole virus vaccine against JE. It is safe, well tolerated, efficacious and can be administered to children, adults and the elderly. The vaccination schedule involves administering 2 doses four weeks apart. For adults, a rapid schedule (0-7 days) is available, which could greatly enhance the feasibility of its use. Healthcare workers should inform both short- and long-term travelers of the risk of JE in each period of the year and recommend vaccination. Indeed, it has been shown that short-term travelers are also at risk, not only in rural environments, but also in cities and coastal towns, especially in tourist localities where excursions to country areas are organized.

Entities:  

Keywords:  IC51 vaccine (IXIARO®); Japanese encephalitis disease; Japanese encephalitis virus; Travel medicine

Mesh:

Substances:

Year:  2018        PMID: 29938245      PMCID: PMC6009073          DOI: 10.15167/2421-4248/jpmh2018.59.1.962

Source DB:  PubMed          Journal:  J Prev Med Hyg        ISSN: 1121-2233


  44 in total

Review 1.  Travel-acquired Japanese encephalitis and vaccination considerations.

Authors:  Androula Pavli; Helena C Maltezou
Journal:  J Infect Dev Ctries       Date:  2015-09-27       Impact factor: 0.968

2.  Immunogenicity and safety of IXIARO (IC51) in a Phase II study in healthy Indian children between 1 and 3 years of age.

Authors:  A Kaltenböck; K Dubischar-Kastner; E Schuller; Mahima Datla; C S Klade; T S A Kishore
Journal:  Vaccine       Date:  2009-10-24       Impact factor: 3.641

3.  Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51.

Authors:  Susanne Eder; Katrin Dubischar-Kastner; Christa Firbas; Tomas Jelinek; Bernd Jilma; Astrid Kaltenboeck; Michael Knappik; Herwig Kollaritsch; Michael Kundi; Maria Paulke-Korinek; Elisabeth Schuller; Christoph S Klade
Journal:  Vaccine       Date:  2011-02-01       Impact factor: 3.641

4.  Safety profile of the Vero cell-derived Japanese encephalitis virus (JEV) vaccine IXIARO(®).

Authors:  Elisabeth Schuller; Anton Klingler; Katrin Dubischar-Kastner; Shailesh Dewasthaly; Zsuzsanna Müller
Journal:  Vaccine       Date:  2011-09-10       Impact factor: 3.641

5.  Origin and evolution of Japanese encephalitis virus in southeast Asia.

Authors:  Tom Solomon; Haolin Ni; David W C Beasley; Miquel Ekkelenkamp; Mary Jane Cardosa; Alan D T Barrett
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

6.  Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO®, JESPECT®) in a pediatric population in JE non-endemic countries: An uncontrolled, open-label phase 3 study.

Authors:  Tomas Jelinek; Michael A Cromer; Jakob P Cramer; Deborah J Mills; Kenneth Lessans; Anthony W Gherardin; Elizabeth D Barnett; Stefan H F Hagmann; Helena H Askling; Sigrid Kiermayr; Vera Kadlecek; Susanne Eder-Lingelbach; Christian Taucher; Katrin L Dubischar
Journal:  Travel Med Infect Dis       Date:  2018-03-13       Impact factor: 6.211

7.  Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial.

Authors:  E Tauber; H Kollaritsch; M Korinek; P Rendi-Wagner; B Jilma; C Firbas; S Schranz; E Jong; A Klingler; S Dewasthaly; C S Klade
Journal:  Lancet       Date:  2007-12-01       Impact factor: 79.321

8.  Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study.

Authors:  E Schuller; B Jilma; V Voicu; G Golor; H Kollaritsch; A Kaltenböck; C Klade; E Tauber
Journal:  Vaccine       Date:  2008-06-17       Impact factor: 3.641

Review 9.  Japanese encephalitis virus infection.

Authors:  Michael J Griffiths; Lance Turtle; Tom Solomon
Journal:  Handb Clin Neurol       Date:  2014

10.  Mapping the spatial distribution of the Japanese encephalitis vector, Culex tritaeniorhynchus Giles, 1901 (Diptera: Culicidae) within areas of Japanese encephalitis risk.

Authors:  Joshua Longbottom; Annie J Browne; David M Pigott; Marianne E Sinka; Nick Golding; Simon I Hay; Catherine L Moyes; Freya M Shearer
Journal:  Parasit Vectors       Date:  2017-03-16       Impact factor: 3.876

View more
  7 in total

Review 1.  From dengue to Zika: the wide spread of mosquito-borne arboviruses.

Authors:  Shivani Sukhralia; Mansi Verma; Shruthi Gopirajan; P S Dhanaraj; Rup Lal; Neeti Mehla; Chhaya Ravi Kant
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-09-28       Impact factor: 3.267

Review 2.  Travel vaccines: Update for Canadian pharmacists.

Authors:  Christina Bascom
Journal:  Can Pharm J (Ott)       Date:  2019-10-11

3.  Axl Alleviates Neuroinflammation and Delays Japanese Encephalitis Progression in Mice.

Authors:  Zhao-Yang Wang; Zi-Da Zhen; Dong-Ying Fan; Pei-Gang Wang; Jing An
Journal:  Virol Sin       Date:  2021-02-03       Impact factor: 4.327

Review 4.  Review of Emerging Japanese Encephalitis Virus: New Aspects and Concepts about Entry into the Brain and Inter-Cellular Spreading.

Authors:  Luis Filgueira; Nils Lannes
Journal:  Pathogens       Date:  2019-07-26

5.  A VLP-Based Vaccine Candidate Protects Mice against Japanese Encephalitis Virus Infection.

Authors:  Limin Yang; Aibo Xiao; Hu Wang; Xiaojuan Zhang; Yuan Zhang; Yunlong Li; Yanqiu Wei; Wenjun Liu; Chuangfu Chen
Journal:  Vaccines (Basel)       Date:  2022-01-26

6.  Japanese encephalitis virus persists in the human reproductive epithelium and porcine reproductive tissues.

Authors:  Subash Chapagain; Prince Pal Singh; Khanh Le; David Safronetz; Heidi Wood; Uladzimir Karniychuk
Journal:  PLoS Negl Trop Dis       Date:  2022-07-29

Review 7.  The Ecology and Evolution of Japanese Encephalitis Virus.

Authors:  Peter Mulvey; Veasna Duong; Sebastien Boyer; Graham Burgess; David T Williams; Philippe Dussart; Paul F Horwood
Journal:  Pathogens       Date:  2021-11-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.